—A recent study suggests that perimenopausal and postmenopausal women report worse bladder health and function compared to their premenopausal counterparts. Additionally, current hormone use was ...

Evaluating therapeutic bladder cancer trial disparities in race/ethnicity. Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized ...

Avelumab plus BSC significantly improved OS and PFS in advanced urothelial carcinoma patients, irrespective of diabetes status, as shown in the JAVELIN Bladder 100 trial. The trial's findings led to ...

The cover for issue 56 of Oncotarget features Figure 5, "HDAC inhibition synergizes with Hsp90 inhibition to induce apoptosis in bladder cancer.," Woodford, et al. The researchers have recently ...

Bavencio shows efficacy and safety in advanced urothelial carcinoma, regardless of diabetes status, as per JAVELIN Bladder 100 trial findings. Diabetes requires careful management in patients ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...

CHAPEL HILL, North Carolina--A new study has demonstrated that patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy treatment in a manner that is ...

N-803 is an IL-15 superagonist complex consisting of an IL-15 mutant bound to an IL-15 receptor α/IgG1 Fc fusion protein The Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

All patients with a Current Procedural Terminology code for transurethral resection of bladder tumor (TURBT; n = 76,060) were selected from the Department of Veterans Affairs (VA) database. A sample ...

Researchers report a study has demonstrated that patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy in a manner that is similar to patients without ...